Recently, biological and preclinical data showed that VEGFR2 inhibition could inhibit tumor-induced angiogenesis.[23] Moreover, several VEGFR2 inhibitors are being evaluated in phase I–III clinical trials. This evidence concerns the gene KDR and neoplasm.